fr   en
Agreement

Tableaux synoptiques (en anglais)


Parcourir par date
Rechercher par mot clé
Date: 2006-01-01
Biotech partner: Biovitrum (Sweden) Symphogen (Denmark)
Pharma Partner:  
Type of agreement: * commercialization/ distribution
* development
Compound: Sym001 (Symphogen's combination of 25 recombinant anti-rhesus D antibodies)
Disease area: idiopathic thrombocytopenic purpura and neonatal haemolytic disease
Development phase: Initiation of clinical studies is planned for 2006.
Nature of the agreement:  
Financial terms of the agreement: Financial details not disclosed.


Go back to previous page